ZACKS·2026-01-16 16:51Core Insights - Eli Lilly and Company's stock declined by 3.8% following the FDA's delay in the decision on its oral GLP-1 drug, orforglipron, now expected on April 10 instead of late March [1][7] Company Overview - Lilly submitted a new drug application (NDA) for orforglipron in December and received a National Priority Voucher from the FDA to expedite the review process [2] - The company's stock has increased by 42.3% over the past year, outperforming the industry average increase of 25.9% [2] Market Dynamics - The GLP-1 obesity market is currently dominated by Lilly and Novo Nordisk, with the latter recently launching the oral version of its obesity drug, Wegovy, priced at $149 per month [3][4] - Daily oral pills are anticipated to be more convenient and potentially cheaper than existing injectable treatments, which could broaden patient adoption [4] Competitive Landscape - Novo Nordisk's approval of the Wegovy pill provides it with a first-to-market advantage, potentially impacting Lilly's market share [8] - Analysts believe Lilly could close the gap in the obesity pill market once orforglipron is approved, now delayed to 2026 [8] Future Prospects - Lilly is also exploring orforglipron for other conditions such as sleep apnea and hypertension, which could enhance its revenue potential beyond obesity [9] - Other companies, including Structure Therapeutics and Viking Therapeutics, are developing their own oral GLP-1 drugs, indicating a competitive landscape in the obesity treatment market [10][11][12]